Glancy Prongay Wolke & Rotter LLP served as Lead Counsel for the certified Settlement Class
LOS ANGELES, Aug. 26, 2026 (GLOBE NEWSWIRE) — The United States District Court for the District of New Jersey granted final approval to a $9,500,000 cash settlement resolving securities fraud claims on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (formerly NASDAQ: EGRX) common stock. The Honorable Michael A. Hammer, United States Magistrate Judge, entered judgment approving the settlement on August 19, 2026, following a settlement fairness hearing held that afternoon.
Glancy Prongay Wolke & Rotter LLP served as Court-appointed Lead Counsel for the Settlement Class, with Carella, Byrne, Cecchi, Brody & Agnello, P.C. serving as Liaison Counsel. The action was brought on behalf of Court-appointed lead plaintiff Evans Associates I, LLC and named plaintiffs Nicholas Miller, Liyu Wang, and Joanna Pluta.
The Settlement Class
The Court certified a Settlement Class consisting of all persons and entities who purchased the publicly traded common stock of Eagle Pharmaceuticals between August 9, 2022 and October 1, 2024, both dates inclusive, and who were damaged thereby. Certain persons and entities are excluded from the Settlement Class by definition, including Eagle’s officers and directors during the class period and their immediate families.
The Allegations
The litigation concerned allegedly false and misleading statements by Eagle Pharmaceuticals and two of its executives, Scott Tarriff and Brian Cahill, regarding the Company’s sales of its oncology drug Pemfexy and the effectiveness of Eagle’s internal controls over financial reporting.
Plaintiffs alleged that Eagle had experienced slower-than-anticipated product pull-through from a wholesale customer and that, as a result, the Company overstated the revenue it reported from Pemfexy sales beginning with the second quarter of 2022. On October 2, 2024, Eagle filed a Form 8-K announcing that its financial statements dating back to the quarter ended June 30, 2022 should no longer be relied upon and would need to be restated. Trading in Eagle common stock was suspended on Nasdaq on October 3, 2024, and the stock thereafter traded on the OTC Expert Market.
Defendants denied and continue to deny all allegations of wrongdoing or liability. The settlement is not an admission of liability by any defendant, and the Court’s judgment makes no finding of wrongdoing.
Claims Deadline
Settlement Class Members who wish to receive a payment from the Net Settlement Fund must submit a valid Claim Form, postmarked or submitted online no later than October 16, 2026. Claim Forms and the full Notice are available at www.EaglePharmaSecuritiesSettlement.com, or from the Claims Administrator at Eagle Pharmaceuticals Securities Litigation, c/o Epiq, P.O. Box 4790, Portland, OR 97208-4790, 1-877-313-8718.
Settlement Class Members who do not submit a timely, valid Claim Form will not share in the distribution but will remain bound by the Court’s judgment and the releases it provides.
The case is Miller v. Eagle Pharmaceuticals, Inc., No. 2:23-cv-23011-MAH (D.N.J.).
About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP is a national law firm representing investors and consumers in complex litigation, with a practice concentrated in securities class actions and shareholder litigation. The firm is headquartered in Los Angeles.
Contact
Garth A. Spencer, Esq.
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
(310) 201-9150 | [email protected]
www.glancylaw.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0c7ca7e3-aab8-4c9a-a3bc-bb7aa98aadbb
